reviewCancerJul 28, 2020HYBRID OA

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

University of Rochester Medical Center · Eastman Chemical Company (United States) · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis.

Methods

The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.

Citation impact

1,259
total citations
FWCI
63.28
Percentile
100%
References
67
Citations per year

Authors

14

Topics & keywords

Keywords
  • Mucositis
  • Medicine
  • Guideline
  • Psychological intervention
  • Intensive care medicine
  • Cancer
  • Clinical Practice
  • Intervention (counseling)
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.